LOVE Fundamental Analysis - CANNARA BIOTECH INC

Fundamental Rating

Taking everything into account, LOVE scores 6 out of 10 in our fundamental rating. LOVE was compared to 4 industry peers in the Personal Care Products industry. LOVE is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. LOVE is evaluated to be cheap and growing strongly. This does not happen too often!

Quickly go to:

1. Profitability

1.1 Basic Checks

LOVE had positive earnings in the past year.

LOVE had a positive operating cash flow in the past year.

The reported net income has been mixed in the past 5 years: LOVE reported negative net income in multiple years.

In multiple years LOVE reported negative operating cash flow during the last 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of 9.12%, LOVE belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.

The Return On Equity of LOVE (15.74%) is better than 100.00% of its industry peers.

		Industry Rank	Sector Rank
ROA	9.12%
ROE	15.74%
ROIC	N/A

ROA(3y)3.63%

ROA(5y)-2.7%

ROE(3y)6.49%

ROE(5y)-3.09%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With an excellent Profit Margin value of 15.15%, LOVE belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.

With a Gross Margin value of 14.02%, LOVE perfoms like the industry average, outperforming 50.00% of the companies in the same industry.

In the last couple of years the Gross Margin of LOVE has declined.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	15.15%
GM	14.02%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-40.07%

GM growth 5Y-41.26%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

LOVE does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, LOVE has less shares outstanding

Compared to 5 years ago, LOVE has more shares outstanding

LOVE has a better debt/assets ratio than last year.

2.2 Solvency

An Altman-Z score of 2.04 indicates that LOVE is not a great score, but indicates only limited risk for bankruptcy at the moment.

The Altman-Z score of LOVE (2.04) is better than 75.00% of its industry peers.

The Debt to FCF ratio of LOVE is 2.92, which is a good value as it means it would take LOVE, 2.92 years of fcf income to pay off all of its debts.

With an excellent Debt to FCF ratio value of 2.92, LOVE belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.

A Debt/Equity ratio of 0.41 indicates that LOVE is not too dependend on debt financing.

LOVE has a better Debt to Equity ratio (0.41) than 100.00% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.41
Debt/FCF	2.92
Altman-Z	2.04

ROIC/WACCN/A

WACC7.12%

2.3 Liquidity

LOVE has a Current Ratio of 2.43. This indicates that LOVE is financially healthy and has no problem in meeting its short term obligations.

LOVE has a better Current ratio (2.43) than 75.00% of its industry peers.

LOVE has a Quick Ratio of 1.01. This is a normal value and indicates that LOVE is financially healthy and should not expect problems in meeting its short term obligations.

With a decent Quick ratio value of 1.01, LOVE is doing good in the industry, outperforming 75.00% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	2.43
Quick Ratio	1.01

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

LOVE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 189.86%, which is quite impressive.

The Revenue has grown by 33.04% in the past year. This is a very strong growth!

LOVE shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 108.26% yearly.

EPS 1Y (TTM)189.86%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%102.26%

Revenue 1Y (TTM)33.04%

Revenue growth 3Y68.19%

Revenue growth 5Y108.26%

Sales Q2Q%39.85%

3.2 Future

LOVE is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 42.03% yearly.

LOVE is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 19.04% yearly.

EPS Next Y43.26%

EPS Next 2Y51.4%

EPS Next 3Y42.03%

EPS Next 5YN/A

Revenue Next Year27.9%

Revenue Next 2Y22.09%

Revenue Next 3Y19.04%

Revenue Next 5YN/A

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

LOVE is valuated reasonably with a Price/Earnings ratio of 9.94.

Based on the Price/Earnings ratio, LOVE is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.

The average S&P500 Price/Earnings ratio is at 27.57. LOVE is valued rather cheaply when compared to this.

LOVE is valuated reasonably with a Price/Forward Earnings ratio of 10.46.

LOVE's Price/Forward Earnings ratio is rather cheap when compared to the industry. LOVE is cheaper than 100.00% of the companies in the same industry.

Compared to an average S&P500 Price/Forward Earnings ratio of 23.09, LOVE is valued rather cheaply.

		Industry Rank	Sector Rank
PE	9.94
Fwd PE	10.46

4.2 Price Multiples

100.00% of the companies in the same industry are more expensive than LOVE, based on the Price/Free Cash Flow ratio.

		Industry Rank	Sector Rank
P/FCF	9.51
EV/EBITDA	N/A

4.3 Compensation for Growth

LOVE's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

A more expensive valuation may be justified as LOVE's earnings are expected to grow with 42.03% in the coming years.

PEG (NY)0.23

PEG (5Y)N/A

EPS Next 2Y51.4%

EPS Next 3Y42.03%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

LOVE does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

CANNARA BIOTECH INC

TSX-V:LOVE (10/22/2025, 7:00:00 PM)

1.69

-0.03 (-1.74%)

Chartmill FA Rating

GICS SectorConsumer Staples

GICS IndustryGroupHousehold & Personal Products

GICS IndustryPersonal Care Products

Earnings (Last)07-28 2025-07-28

Earnings (Next)11-24 2025-11-24

Inst Owners0.24%

Inst Owner ChangeN/A

Ins Owners27.72%

Ins Owner ChangeN/A

Market Cap154.52M

Revenue(TTM)102.43M

Net Income(TTM)15.52M

Analysts80

Price Target3.06 (81.07%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	9.94
Fwd PE	10.46
P/S	1.51
P/FCF	9.51
P/OCF	7.58
P/B	1.57
P/tB	1.57
EV/EBITDA	N/A

EPS(TTM)0.17

EY10.06%

EPS(NY)0.16

Fwd EY9.56%

FCF(TTM)0.18

FCFY10.52%

OCF(TTM)0.22

OCFY13.18%

SpS1.12

BVpS1.08

TBVpS1.08

PEG (NY)0.23

PEG (5Y)N/A

Graham Number2.03

Profitability

		Industry Rank	Sector Rank
ROA	9.12%
ROE	15.74%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	15.15%
GM	14.02%
FCFM	15.87%

ROA(3y)3.63%

ROA(5y)-2.7%

ROE(3y)6.49%

ROE(5y)-3.09%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-40.07%

GM growth 5Y-41.26%

F-Score8

Asset Turnover0.6

Health

		Industry Rank	Sector Rank
Debt/Equity	0.41
Debt/FCF	2.92
Debt/EBITDA	N/A
Cap/Depr	66.23%
Cap/Sales	4.02%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	104.74%
Current Ratio	2.43
Quick Ratio	1.01
Altman-Z	2.04

F-Score8

WACC7.12%

ROIC/WACCN/A

Cap/Depr(3y)228.25%

Cap/Depr(5y)410.31%

Cap/Sales(3y)22.24%

Cap/Sales(5y)120%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)189.86%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%102.26%

EPS Next Y43.26%

EPS Next 2Y51.4%

EPS Next 3Y42.03%

EPS Next 5YN/A

Revenue 1Y (TTM)33.04%

Revenue growth 3Y68.19%

Revenue growth 5Y108.26%

Sales Q2Q%39.85%

Revenue Next Year27.9%

Revenue Next 2Y22.09%

Revenue Next 3Y19.04%

Revenue Next 5YN/A

EBIT growth 1Y33.33%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3Y60.25%

EBIT Next 5YN/A

FCF growth 1Y228.78%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y3771.44%

OCF growth 3YN/A

OCF growth 5YN/A

CANNARA BIOTECH INC (LOVE.CA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens